Drug Trial Radar · NCT07885917
Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
218
Planned (sponsor's estimate)
Start
Dec 10, 2026
Primary completion
Apr 1, 2030
Study completion Apr 1, 2030
Sponsor
- Lead sponsor
- Azafaros B.V.Industry
- Sponsor type
- Industry
- First posted
- Oct 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label extension trial to evaluate the long-term safety and tolerability of nizubaglustat (AZ-3102) in participants with rare lysosomal disorders who have participated in a previous nizubaglustat trial and wish to continue nizubaglustat treatment.
Conditions
- Niemann-Pick Disease Type C
- GM2 Gangliosidosis
- GM1 Gangliosidosis
- Gaucher Disease Type 3
Interventions
AZ-3102Drug
Daily oral intake of nizubaglustat (AZ-3102) dispersible tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Through study completion, an average of 4 years
- The Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Through study completion, an average of 4 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.